

S1 Table. Baseline characteristics of all patients (n=682)

Characteristic	No. (%)
Age (yr), median (range)	47 (25-80)
Histologic grade	
I-II	404 (59.2)
II	278 (40.8)
Molecular subtype	
Luminal HER2(-)	309 (45.3)
HER2(+)	262 (38.4)
Triple-negative	111 (16.3)
Ki-67 (%)	
< 15	341 (50.0)
≥ 15	341 (50.0)
Resection margin status	
Negative	630 (92.4)
Close	52 (7.6)
Axillary surgery	
SLNB	192 (28.2)
ALND	490 (71.8)
Lymphovascular invasion	
Absent	429 (62.9)
Present	253 (37.1)
Clinical T category	
cT1-2	378 (55.4)
cT3-4	304 (44.6)
Clinical N category	
cN0	10 (1.5)
cN1	265 (38.9)
cN2-3	407 (59.6)
ypT category	
ypT0-is	148 (21.7)
ypT1	226 (33.1)
ypT2-4	308 (45.2)
ypN category	
ypN0	314 (46.0)

ypN1	213 (31.2)
ypN2-3	155 (22.7)
Pathological response	
ypCR	135 (19.8)
No ypCR	547 (80.2)
Anti-HER2 therapy	
No	420 (61.6)
Yes	262 (38.4)
Adjuvant endocrine therapy	
No	238 (34.9)
Yes	444 (65.1)
Adjuvant chemotherapy	
No	613 (89.9)
Yes	69 (10.1)
Radiation therapy	
No	86 (12.6)
Yes	596 (87.4)

ALND, axillary lymph node dissection; HER2, human epidermal growth factor receptor; pCR, pathologic complete response; SLNB, sentinel lymph node biopsy.